Keys To Addressing MRSA In The Diabetic Foot
Dr. Garr is a first-year resident with the VA Puget Sound Healthcare System in Seattle.
1. Kallen AJ, Mu Y, Bulens S, et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA. 2010; 304(6):641-8.
2. Dang CN, Prasad YDM, Boulton AJ, Jude EB. Methicillin-Resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabetic Medicine. 2003; 20(2):159-161.
3. Yates C, May K, Hale T, et al. Wound chronicity, inpatient care, and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers. Diabetes Care. 2009; 32(10):1907-9.
4. Lipsky BA, Berendt, AR, Cornia PB, et al. 2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections. Clin Infect Dis. 2012; 54(12):132-173.
5. Thompson S, Townsend R. Pharmacological agents for soft tissue and bone infected with MRSA: which agent and for how long? Injury. 2011; 42 Suppl 5:S7-10.
6. Pfeltz RF, Wilkinson BJ. The escalating challenge of vancomycin resistance in Staphylococcus aureus. Curr Drug Targets Infect Disord. 2004; 4(4):273-94.
7. Bodmann KF, Heizmann WR, von Eiff C, et al. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities. Chemotherapy. 2012; 58(4):282-94.
8. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004; 38(12):1673-81.
9. Rogers LC, Bevilacqua NJ. MRSA In The Diabetic Foot. Podiatry Management. 2009; 28(9);127-32.
10. Centers for Disease Control and Prevention: MRSA Statistics. Available at http://www.cdc.gov/mrsa/statistics/index.html .